Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

Bullboard (TSXV:TLT)

View:
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
Comment by Eoganachton Jun 25, 2024 9:58pm

RE:RE:RE:RE:RE:RE:3rd quarter

Hi John - maybe the FDA is just being extra careful with a non-mainstream NMIBC treatment type with a dubious past. Photofrin PDT was approved by HC for NMIBC in 1993 before it was recognized that it ...more  
91
Discussion
Comment by plantraderon Jun 25, 2024 9:24pm

RE:RE:RE:RE:RE:3rd quarter

@eog, Thanks. That is a little bit of potential assurance. But we can't exactly go by what the company thinks, since as RDW said the FDA calls the shots. Hopefully he's right in his ...more  
81
Discussion
Comment by N0taP00pon Jun 25, 2024 8:30pm

RE:RE:RE:RE:RE:RE:3rd quarter

Good insights, Eoganacht.Took a look at LabCorp.com , page titled What Does A central Lab Do?   In this case, if the FDA requested them to take every result and replicate it at one of these ...more  
89
Discussion
Comment by Johnandrose22on Jun 25, 2024 7:20pm

RE:RE:RE:RE:RE:3rd quarter

Thanks, as always, Eoganacht! My question arises from Mr. White's summary of local/central pathology and concordance and the accuracy of one to another.  Mr. White found the "ask" ...more  
130
Discussion
Comment by Eoganachton Jun 25, 2024 6:04pm

RE:What if

I think we're being treated the same as any other trial sponsor. Novartis is a big pharma and look at the hoops they had to junp through to get a BTD... https://stockhouse.com/companies/bullboard ...more  
143
Discussion
Post by sade69on Jun 25, 2024 5:33pm

What if

Ruvidar was develop By a big pharma, Pfiizer, Bristol, etc. Do you think BTD and AA would be already accept and people save or cure ?
103
Discussion
Comment by Eoganachton Jun 25, 2024 4:55pm

RE:RE:RE:RE:3rd quarter

It's clearly not a concern as far as Roger is concerned. "...it was a bit of a surprise for us that they insisted on central pathology. Because the concordance level of local pathology ...more  
199
Discussion
Comment by Legit62on Jun 25, 2024 4:35pm

RE:RE:RE:PDT is the future of cancer treatment.

Unfortunately , big pharma always there, i had a career in medicine and they are always on your shoulder, pushing ,our technology is grate for patients. I hope one day this science works and patients ...more  
122
Discussion
Comment by Legit62on Jun 25, 2024 4:32pm

RE:RE:PDT is the future of cancer treatment.

Your right cancerslayer, it should be about the patient, not Big Pharma profits
59
Discussion
Comment by BlueFrankyon Jun 25, 2024 4:22pm

RE:PDT is the future of cancer treatment.

Thanks wildbird1 .. appreciate your efforts as always!
52
Discussion
Comment by CancerSlayeron Jun 25, 2024 4:08pm

RE:PDT is the future of cancer treatment.

Thanks for sharing wildbird1... The simple reality is that patients deserve options.  Current options are not simple & require patient/time-intensive forms of treatment.  We offer ...more  
120
Discussion
Comment by Donein25on Jun 25, 2024 3:31pm

RE:RE:RE:RE:3rd quarter

very good point. I raised this very issue at AGM. As you undoubtedly noticed the most recent data showed a 5% decrease in CR across the board. We may see more of this CR adjustment in the near term ...more  
133
Discussion
Post by Tarbabyon Jun 25, 2024 3:05pm

Virus Elimination.

If Rutherrin can eliminate almost any virus In a person...wow that alone should make this a $ Billion company. Herpes and HPV are the two big ones. HPV is causing a huge cancer load on the system. But ...more  
146
Post by wildbird1on Jun 25, 2024 3:01pm

PDT is the future of cancer treatment.

In this link...[url=https://ncbi,nlm.nih.gov/pmc/articles/PMC9913255/][/url] 3. Conclusions '' As a non-invasive therapy method, PDT has obtained significant progress in recent years ...more  
161
Discussion
Comment by plantraderon Jun 25, 2024 3:00pm

RE:RE:RE:3rd quarter

Right now IMO one concern is that the "central pathology" analysis finds inconsistencies in how the tissue or data was analyzed previously as part of the results the company has been ...more  
112
Discussion
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT

Visit Facebook Visit X Visit Linked In Visit Instagram Visit Youtube



INVESTORS & MEDIA OVERVIEW FINANCIAL FILINGS PRESENTATIONS MEDIA FACT SHEETS MANAGEMENT

Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250